# NovoCure Ltd (NVCR)

Informational only - not investment advice.

CIK: 0001645113
SIC: 3841 Surgical & Medical Instruments & Apparatus
SIC breadcrumb: [Manufacturing](/division/D/) > [SIC Major Group 38](/major-group/38/) > [SIC 3841 Surgical & Medical Instruments & Apparatus](/industry/3841/)
Latest 10-K filed: 2026-02-26
SEC page: https://www.sec.gov/edgar/browse/?CIK=1645113
Filing source: https://www.sec.gov/Archives/edgar/data/1645113/000164511326000017/nvcr-20251231.htm

## At a glance

FY2025 · period end 2025-12-31 · filed 2026-02-26 · accession 0001645113-26-000017 · source: https://data.sec.gov/api/xbrl/companyfacts/CIK0001645113.json

| Metric | Value | FY | Provenance |
| --- | ---: | ---: | --- |
| Revenue | 655,353,000 USD | 2025 | verified |
| Net income | -136,227,000 USD | 2025 | verified |
| Assets | 804,326,000 USD | 2025 | verified |
| Free cash flow | -75,679,000 USD | 2025 | computed |
| Net margin | -20.79% | 2025 | computed |
| Operating margin | -23.47% | 2025 | computed |
| Revenue YoY | +8.28% | 2025 | computed |
| ROE | -40.01% | 2025 | computed |

Computed values are grepcent-computed from the verified facts above and may differ from ratios the company itself reports. Free cash flow = operating cash flow − capital expenditures. Net margin = net income ÷ revenue. Operating margin = operating income ÷ revenue. Revenue YoY = FY2025 revenue ÷ FY2024 revenue − 1 (consecutive fiscal years only). ROE = net income ÷ period-end stockholders' equity.

No market price, no rating, no forecast on this site. Not investment advice.

### Peer percentile fingerprint

| Ratio | NVCR | Peer median | Percentile | N |
| --- | ---: | ---: | ---: | ---: |
| Net margin | -20.8% | -6.0% | 32 | 63 |
| Operating margin | -23.5% | -2.7% | 27 | 63 |
| Revenue growth | 8.3% | 13.6% | 32 | 64 |
| FCF margin | -11.5% | 0.2% | 29 | 63 |
| ROE | -40.0% | -9.1% | 19 | 58 |
| ROA | -16.9% | -4.8% | 34 | 65 |
| Liabilities / equity | 1.36 | 0.89 | 65 | 63 |
| Current ratio | 2.90 | 3.23 | 44 | 65 |

Percentile = share of the N covered peers reporting that ratio whose value is lower (ties counted half); computed among grepcent-covered companies in SIC industry 3841 Surgical & Medical Instruments & Apparatus, not the whole market. A higher percentile means a higher value of the ratio, not a better company. Ratios with fewer than 8 reporting peers are omitted. Latest reported values per company; fiscal periods may differ. Descriptive arithmetic - not a score, rating, or ranking.

## Selected Fundamentals
| Metric | Value | Unit | FY | Filed |
| --- | ---: | --- | ---: | --- |
| Revenue | 655353000 | USD | 2025 | 2026-02-26 |
| Net income | -136227000 | USD | 2025 | 2026-02-26 |
| Assets | 804326000 | USD | 2025 | 2026-02-26 |

## Financials

Annual standardized facts from SEC companyfacts as of latest extracted filing date 2026-02-26. Source: https://data.sec.gov/api/xbrl/companyfacts/CIK0001645113.json. Derived margins, ratios, and free cash flow are computed from the extracted annual SEC facts.

| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | 82,888,000 | 177,026,000 | 248,069,000 | 351,318,000 | 494,366,000 | 535,031,000 | 537,840,000 | 509,338,000 | 605,220,000 | 655,353,000 |
| Net income | -131,845,000 | -61,662,000 | -63,559,000 | -7,230,000 | 19,808,000 | -58,351,000 | -92,534,000 | -207,043,000 | -168,627,000 | -136,227,000 |
| Operating income | -115,317,000 | -39,328,000 | -33,672,000 | -914,000 | 30,401,000 | -44,333,000 | -89,523,000 | -232,870,000 | -170,496,000 | -153,800,000 |
| Gross profit | 36,606,000 | 121,417,000 | 168,021,000 | 262,712,000 | 387,865,000 | 420,154,000 | 422,973,000 | 381,058,000 | 468,039,000 | 488,474,000 |
| Diluted EPS |  |  | -0.69 | -0.07 | 0.18 | -0.56 | -0.88 | -1.95 | -1.56 | -1.22 |
| Operating cash flow | -107,592,000 | -33,134,000 | -1,865,000 | 26,620,000 | 99,148,000 | 82,756,000 | 30,788,000 | -73,336,000 | -26,369,000 | -49,031,000 |
| Capital expenditures | 5,673,000 | 7,366,000 | 6,711,000 | 10,485,000 | 14,968,000 | 24,170,000 | 21,358,000 | 27,093,000 | 42,855,000 | 26,648,000 |
| Assets | 282,081,000 | 265,298,000 | 339,793,000 | 479,448,000 | 1,051,983,000 | 1,139,495,000 | 1,191,648,000 | 1,146,129,000 | 1,240,784,000 | 804,326,000 |
| Liabilities | 139,736,000 | 151,734,000 | 227,534,000 | 261,658,000 | 575,457,000 | 729,001,000 | 750,478,000 | 783,633,000 | 880,605,000 | 463,860,000 |
| Stockholders' equity | 142,345,000 | 113,564,000 | 112,259,000 | 217,790,000 | 476,526,000 | 410,494,000 | 441,170,000 | 362,496,000 | 360,179,000 | 340,466,000 |
| Cash and cash equivalents | 99,780,000 | 78,592,000 | 140,622,000 | 177,321,000 | 234,674,000 | 208,802,000 | 115,326,000 | 240,821,000 | 163,767,000 | 93,548,000 |
| Free cash flow | -113,265,000 | -40,500,000 | -8,576,000 | 16,135,000 | 84,180,000 | 58,586,000 | 9,430,000 | -100,429,000 | -69,224,000 | -75,679,000 |

### Ratios

ROE and ROA use period-end equity/assets. Liabilities / equity uses total liabilities divided by stockholders' equity. Current ratio uses current assets divided by current liabilities when both are reported.

| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Net margin |  | -34.83% | -25.62% | -2.06% | 4.01% | -10.91% | -17.20% | -40.65% | -27.86% | -20.79% |
| Operating margin | -139.12% | -22.22% | -13.57% | -0.26% | 6.15% | -8.29% | -16.64% | -45.72% | -28.17% | -23.47% |
| Return on equity | -92.62% | -54.30% | -56.62% | -3.32% | 4.16% | -14.21% | -20.97% | -57.12% | -46.82% | -40.01% |
| Return on assets | -46.74% | -23.24% | -18.71% | -1.51% | 1.88% | -5.12% | -7.77% | -18.06% | -13.59% | -16.94% |
| Liabilities / equity | 0.98 | 1.34 | 2.03 | 1.20 | 1.21 | 1.78 | 1.70 | 2.16 | 2.44 | 1.36 |
| Current ratio | 7.10 | 4.88 | 4.98 | 5.10 | 8.80 | 7.53 | 7.00 | 5.78 | 1.46 | 2.90 |

## As-reported value updates

2 tracked differences above grepcent's stated thresholds were found between the earliest XBRL-filed value and the value currently on file for the same fiscal period.

Ledger: /company/NVCR/revisions/


## Quarterly

Quarterly standardized facts from SEC companyfacts as of latest extracted filing date 2026-07-23. Source: https://data.sec.gov/api/xbrl/companyfacts/CIK0001645113.json.

Flow metrics use discrete quarter-length periods from 10-Q/10-Q/A filings. Q4 revenue and net income are derived only when annual FY and nine-month YTD facts exist for the same fiscal year; derived Q4 values are labeled. EPS Q4 is not derived.

| Quarter | End date | Revenue | Net income | Diluted EPS | Method |
| --- | --- | ---: | ---: | ---: | --- |
| 2022-Q3 | 2022-09-30 |  |  | -0.25 | reported discrete quarter |
| 2023-Q1 | 2023-03-31 |  |  | -0.50 | reported discrete quarter |
| 2023-Q2 | 2023-06-30 |  |  | -0.54 | reported discrete quarter |
| 2023-Q3 | 2023-06-30 |  | -57,418,000 |  | reported discrete quarter |
| 2023-Q3 | 2023-09-30 | 127,321,000 |  | -0.46 | reported discrete quarter |
| 2023-Q4 | 2023-12-31 | 133,784,000 | -47,079,000 |  | derived Q4 = FY annual - nine-month YTD |
| 2024-Q1 | 2024-03-31 | 138,503,000 | -38,760,000 | -0.36 | reported discrete quarter |
| 2024-Q2 | 2024-03-31 |  | -38,760,000 |  | reported discrete quarter |
| 2024-Q2 | 2024-06-30 | 150,356,000 |  | -0.31 | reported discrete quarter |
| 2024-Q3 | 2024-06-30 |  | -33,375,000 |  | reported discrete quarter |
| 2024-Q3 | 2024-09-30 | 155,095,000 |  | -0.28 | reported discrete quarter |
| 2024-Q4 | 2024-12-31 | 161,266,000 | -65,922,000 |  | derived Q4 = FY annual - nine-month YTD |
| 2025-Q1 | 2025-03-31 | 154,994,000 | -34,319,000 | -0.31 | reported discrete quarter |
| 2025-Q2 | 2025-03-31 |  | -34,319,000 |  | reported discrete quarter |
| 2025-Q2 | 2025-06-30 | 158,805,000 |  | -0.36 | reported discrete quarter |
| 2025-Q3 | 2025-06-30 |  | -40,139,000 |  | reported discrete quarter |
| 2025-Q3 | 2025-09-30 | 167,204,000 |  | -0.33 | reported discrete quarter |
| 2025-Q4 | 2025-12-31 | 174,350,000 | -24,499,000 |  | derived Q4 = FY annual - nine-month YTD |
| 2026-Q1 | 2026-03-31 | 174,055,000 | -71,138,000 | -0.62 | reported discrete quarter |
| 2026-Q2 | 2026-03-31 |  | -71,138,000 |  | reported discrete quarter |
| 2026-Q2 | 2026-06-30 | 183,584,000 |  | -0.13 | reported discrete quarter |

## Filed narrative (10-K & 10-Q)

## Business

Verbatim Item 1 Business section from NVCR's latest 10-K: [/company/NVCR/business/](/company/NVCR/business/).

## Risk Factors

Verbatim Item 1A Risk Factors from NVCR's latest 10-K: [/company/NVCR/risk-factors/](/company/NVCR/risk-factors/).

## Latest quarter (10-Q)

Latest 10-Q source: https://www.sec.gov/Archives/edgar/data/1645113/000164511326000062/nvcr-20260630.htm

Extracted structurally from real Item 2 body heading to real Item 3/4 boundary.
Confidence: high
Filing date: 2026-07-23
Report date: 2026-06-30

Item 2.  Management’s Discussion and Analysis of Financial Condition and Results of Operations

Management’s Discussion and Analysis of Financial Condition and Results of Operations (“MD&A”) is intended to provide information to assist you in better understanding and evaluating our financial condition and results of operations. We encourage you to read this MD&A in conjunction with our unaudited consolidated financial statements and the notes thereto for the period ended June 30, 2026 included in Part I, Item 1 of this Quarterly Report on Form 10-Q. This discussion contains forward-looking statements that involve risks and uncertainties. Please refer to the information under the heading “Cautionary Note Regarding Forward-Looking Statements” elsewhere in this report. References to the words “we,” “our,” “us,” and the “Company” in this report refer to NovoCure Limited, including its consolidated subsidiaries.

Critical Accounting Policies and Estimates

In accordance with U.S. generally accepted accounting principles (“GAAP”), in preparing our financial statements, we must make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of net revenues and expenses during the reporting period. We develop and periodically change these estimates and assumptions based on historical experience and on various other factors that we believe are reasonable under the circumstances. Actual results may differ from these estimates.

The critical accounting policies requiring estimates, assumptions and judgments that we believe have the most significant impact on our consolidated financial statements can be found in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025 (the "2025 10-K"). For additional information, see Note 1 to our unaudited consolidated financial statements in Part I, Item 1 of this Quarterly Report. There were no other material changes to our critical accounting policies and estimates as compared to the critical accounting policies and estimates described in our 2025 10-K.

Overview

We are a global oncology company with a proprietary platform technology called Tumor Treating Fields ("TTFields"), which are electric fields that exert physical forces to kill cancer cells. Our therapy is delivered through a medical device. Our key priorities are to drive commercial adoption of Optune Gio®, Optune Lua®, and Optune Pax® (collectively, our "Products"), our commercial TTFields therapy devices, obtain regulatory approval to market TTFields therapy devices in new indications, such as brain metastases from non-small cell lung cancer ("NSCLC"), and to advance clinical and product development programs intended to extend overall survival in some of the most aggressive forms of cancer.

Optune Gio is approved by the U.S. Food and Drug Administration ("FDA") under the Premarket Approval ("PMA") pathway for the treatment of adult patients with newly diagnosed glioblastoma ("GBM") together with temozolomide, a chemotherapy drug, and for adult patients with GBM following confirmed recurrence after chemotherapy as monotherapy treatment. We also have a CE certificate to market Optune Gio for the treatment of GBM in the European Union ("EU"), as well as approval or local registration in the United Kingdom ("UK"), Japan, Canada and certain other countries.

Optune Lua is approved by the FDA under the PMA pathway for the treatment of adult patients with metastatic NSCLC concurrent with PD-1/PD-L1 inhibitors or docetaxel following progression on or after a platinum-based regimen. We also have a CE certificate to market Optune Lua concurrent with PD-1/PD-L1 inhibitors or docetaxel following progression on or after a platinum-based regimen for the treatment of metastatic NSCLC in the EU. In addition, we received regulatory approval in Japan for the use of Optune Lua for the treatment of adult patients with unresectable advanced/recurrent NSCLC concurrent with PD-1/PD-L1 inhibitors following progression on or after a platinum-based regimen.

Optune Lua is also approved by the FDA under the Humanitarian Device Exemption ("HDE") pathway for the treatment of adult patients with malignant pleural mesothelioma or pleural mesothelioma (together, "MPM") together with standard chemotherapies. We have also have a CE certificate in the EU and approval or local registration to market Optune Lua for the treatment of MPM in certain other countries.

Optune Pax is approved by the FDA under the PMA pathway for the treatment of adult patients with locally advanced pancreatic cancer concurrent with gemcitabine and nab-paclitaxel. We also have a CE certificate to market Optune Pax for the treatment of adult patients with locally advanced pancreatic cancer of exocrine origin,

18

Table of Contents

concomitant with gemcitabine and nab-paclitaxel in accordance with guideline recommendations. We have submitted the regulatory application required to market Optune Pax in Japan.

We market our Products in multiple countries around the globe with the majority of our revenues coming from the use of Optune Gio in the U.S., Germany, France and Japan. We are actively evaluating opportunities to expand access to Optune Gio, Optune Lua and Optune Pax in additional international markets.

We have established coverage policies with both public and private payers for the use of Optune Gio in our active markets. In March, we announced the approval of a national reimbursement coverage policy in Japan for the use of Optune Lua for the treatment of NSCLC. We are actively pursuing coverage policies with payers to expand access to our Products and in the meantime we will bill and seek reimbursement from payers on an individual case basis, as applicable.

In September 2025, we presented final data from the Phase 3 METIS clinical trial evaluating the use of TTFields therapy and best supportive care for the treatment of adult patients (n=298) with 1-10 brain metastases from NSCLC following stereotactic radiosurgery ("METIS") at the 2025 American Society for Radiation Oncology Annual Meeting. The METIS trial met its primary endpoint, demonstrating a statistically significant improvement in time to intracranial progression for patients treated with TTFields therapy and supportive care compared to patients treated with supportive care alone. In December 2025, we submitted the final module of our PMA application with the FDA seeking approval for the use of TTFields therapy for the treatment of brain metastases from NSCLC under the brand name Optune Mya®.

In March, we announced topline results from the Phase 2 PANOVA-4 clinical trial ("PANOVA-4") evaluating the use of TTFields therapy together with atezolizumab, gemcitabine and nab-paclitaxel (collectively, "systemic therapies") for the treatment of metastatic pancreatic cancer. PANOVA-4 met its pre-specified primary endpoint, achieving a statistically significant improvement in disease control rate (DCR) compared to the DCR reported in the Phase 3 MPACT study used as the historical control. Patients in PANOVA-4 achieved a DCR of 74% compared 48% in patients receiving gemcitabine and nab-paclitaxel alone (N=431) in the MPACT trial (difference = 26.4%, 1-sided p-value 0.001). Secondary endpoint analyses for overall survival (OS) and objective response rate (ORR) were also completed, with PANOVA-4 patients exhibiting a median OS of 9.7 months and ORR of 34.6% (95% CI, 24.2% - 46.2%). Median duration of treatment with TTFields therapy was 25.6 weeks and six cycles of systemic therapies. TTFields therapy was well-tolerated and device related safety was consistent with prior clinical studies.

In June, we announced topline results from the Phase 3 TRIDENT trial ("TRIDENT"), evaluating the initiation of TTFields therapy at the start of chemoradiation ("Early Start Arm") compared to initiation of TTFields therapy during the maintenance phase of treatment ("Maintenance Start Arm"), following completion of chemoradiation, for the treatment of newly diagnosed GBM. TRIDENT did not show a statistically significant improvement in the primary endpoint of overall survival. Patients randomized to the Early Start Arm demonstrated a median overall survival of 17.7 months compared to 17.5 months in the Maintenance Start Arm (HR 0.953; p=0.519). Survival results in both study arms were durable over a long-term period. One-, two-, and three-year survivals rates in the Early Start Arm were 70.9%, 33.9%, and 22.5%, respectively, and 72.0%, 31.6%, and 18.4%, respectively, in the Maintenance Start Arm. TTFields therapy was well-tolerated and device related safety was consistent with prior clinical studies. Full results from the TRIDENT trial have been accepted for presentation at the American Society for Radiation Oncology 2026 Annual Meeting.

In June, we announced that we received a CE certificate to market Optune Pax for the first-line treatment of locally advanced pancreatic cancer of exocrine origin, concomitant with gemcitabine and nab-paclitaxel (gem/nab-pac) in accordance with guideline recommendations. The CE Mark is supported by data from the Phase 3 PANOVA-3 trial ("PANOVA-3"), which demonstrated a statistically significant improvement in median OS for patients treated with Optune Pax and gem/nab-pac, compared to patients who received gem/nab-pac alone, while also significantly extending time to pain progression. Because the use of gem/nab-pac may vary by market, the approved CE certificate intended purpose for Optune Pax includes a reference to guideline recommendations to account for local differences. We began certifying prescribing physicians for Optune Pax in Germany in July.

We believe the physical mechanisms of action behind TTFields therapy may be broadly applicable to solid tumor cancers. We have several ongoing clinical trials which further explore the use of TTFields therapy in these solid tumor cancers, including our Phase 3 KEYNOTE D58 trial in GBM, which we expect to complete enrollment by the end of 2026, and our Phase 3 LUNAR-2 trial in NSCLC. We anticipate expanding our clinical pipeline over time to study the safety and efficacy of TTFields therapy for our existing and additional solid tumor indications and for use together with other cancer treatment modalities.

19

Table of Contents

We are exploring options to modify our LUNAR-2 trial design with the goals of compressing the timeline to completion and significantly reducing costs. We anticipate engaging with regulators in the coming months regarding potential protocol revisions to streamline the trial’s primary endpoints with the goal of reducing the patient sample size.

We have several product development programs underway that are designed to optimize the delivery of TTFields to the target tumor and enhance patient ease of use. Our intellectual property portfolio contains hundreds of issued patents and numerous patent applications pending worldwide. We believe we possess global commercialization rights to our Products in oncology and are well-positioned to extend those rights into the future as we continue to find innovative ways to improve our Products.

In 2018, we granted Zai Lab (Shanghai) Co., Ltd. ("Zai") a license to commercialize our Products in China, Hong Kong, Macau and Taiwan ("Greater China") under a License and Collaboration Agreement (the "Zai Agreement"). The Zai Agreement also establishes a development partnership intended to accelerate the development of TTFields therapy in multiple solid tumor cancer indications. For additional information, see Note 13 to the Annual Consolidated Financial Statements.

We view our operations and manage our business in one operating segment. For the three and six months ended June 30, 2026, our net revenues were $183.6 million and $357.6 million, respectively. Our net loss for the three and six months ended Jun

[Excerpt truncated for page length; source filing is linked above.]

## Latest 10-K MD&A (excerpt)

Latest 10-K Item 7 source: https://www.sec.gov/Archives/edgar/data/1645113/000164511326000017/nvcr-20251231.htm
Complete FY 2025 MD&A: /company/NVCR/mda/fy2025/

Extracted structurally from real Item 7 body heading to real Item 7A/8 boundary.
Confidence: high
Filing date: 2026-02-26
Report date: 2025-12-31

ITEM 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Management’s Discussion and Analysis of Financial Condition and Results of Operations ("MD&A") is intended to provide information to assist you in better understanding and evaluating our financial condition and results of operations. We encourage you to read this MD&A in conjunction with our consolidated financial statements and the notes thereto included in Part II, Item 8 of this Annual Report on Form 10-K. This discussion contains forward-looking statements that involve risks and uncertainties. Please refer to the information under the heading "Cautionary Note Regarding Forward-Looking Statements" elsewhere in this report. References to the words "we," "our," "us," and the "Company" in this report refer to NovoCure Limited, including its consolidated subsidiaries.

Commentary on Results of Operations

Net revenues

Our revenues are primarily derived from patients using our Products in our active markets. We charge for treatment with our Products on a monthly basis. Our potential net revenues per patient are determined by our ability to secure payment, the monthly fee we collect and the number of months that the patient remains on therapy.

We also receive revenues pursuant to the Zai Agreement. For additional information regarding the Zai Agreement, see Note 12 to the Consolidated Financial Statements.

Cost of revenues

We contract with third parties to manufacture our Products. Our cost of revenues is primarily comprised of the following:

•disposable arrays;

•depreciation expense for the field equipment, including the electric field generator used by patients; and

•personnel and overhead costs such as facilities, freight and depreciation of property, plant and equipment associated with managing our inventory, warehousing and order fulfillment functions.

Operating expenses

Our operating expenses consist of research, development and clinical studies, sales and marketing and general and administrative expenses. Personnel costs are a significant component for each category of operating expenses and consist of wages, benefits and bonuses. Personnel costs also include share-based compensation.

Research, development and clinical studies

Our research, development and clinical studies activity is focused on advancing TTFields therapy through clinical studies across multiple solid tumor types and improving the efficacy and usability of our devices. Research, development and clinical studies costs, including direct and allocated expenses, are expensed as incurred and consist primarily of the following:

•personnel costs for those employees involved in our preclinical and basic research, clinical development programs, clinical affairs, product development and regulatory activities;

•costs to conduct research, product development and clinical study activity through agreements with contract research organizations and other third parties;

•manufacturing expenses associated with our Products, including durable components and disposable arrays, utilized in clinical studies and other research;

•costs associated with publications, presentations and investigator-sponsored trials;

•professional fees related to regulatory approvals and conformity assessment procedures; and

•facilities, depreciation and other allocated expenses, which include direct and allocated expenses for rent and maintenance of facilities, depreciation of leasehold improvements and equipment and laboratory and other supplies.

49

The following table summarizes our research, development and clinical study expenses by program for the years ended December 31, 2025, 2024 and 2023:

[[GREPCENT_TABLE]]
[["","","Year ended December 31,"],["U.S. dollars in thousands","","2025","","2024","","2023"],["Preclinical and basic research","","$","19,990","","","$","18,827","","","$","18,936"],["Clinical development programs:"],["LUNAR","","480","","","1,842","","","6,846"],["LUNAR - 2","","23,117","","","14,645","","","2,999"],["INNOVATE - 3","","8","","","184","","","7,810"],["METIS","","1,565","","","5,399","","","5,758"],["PANOVA - 3","","4,518","","","9,535","","","18,243"],["KEYNOTE D58","","16,807","","","5,651","","","241"],["TRIDENT","","13,021","","","18,369","","","20,348"],["Other clinical studies","","12,056","","","13,375","","","6,960"],["Clinical administration","","20,271","","","19,858","","","25,363"],["Product development","","25,621","","","18,519","","","18,219"],["Clinical affairs","","6,336","","","7,023","","","15,935"],["Other research and development costs (1)","","55,216","","","43,702","","","43,577"],["Share based compensation","","25,538","","","32,716","","","31,827"],["Research, development and clinical studies","","$","224,544","","","$","209,645","","","$","223,062"]]
[[/GREPCENT_TABLE]]

(1)    Other research, development and clinical study costs include regulatory affairs, quality assurance, intellectual property, product safety, allocated facilities and other overhead costs.

We are committed to investing strategically to maximize the growth potential of the TTFields therapy platform. As such, we are prioritizing clinical programs which have the greatest value potential in solid tumors where TTFields therapy has established efficacy and an unmet clinical need for biophysical treatment exists, including glioblastoma, pancreatic cancer and non-small cell lung cancer.

Sales and marketing

Sales and marketing expenses consist primarily of personnel costs, travel, marketing and promotional activities, medical education, market access, commercial shipping and facilities costs. Over the next few years, we expect to continue to make significant expenditures associated with selling and marketing our Products, primarily in connection with continued commercialization in North America, the EU and Japan for the treatment of our approved indications. We will continue to prioritize launch readiness, including field-based commercial and field-based medical team hiring, for the anticipated approval of TTFields therapy for the treatment of pancreatic cancer outside the United States and for future new indications around the world.

General and administrative

General and administrative expenses consist primarily of personnel, professional fees and facilities costs. General and administrative personnel costs include our executive, finance, human resources, information technology and legal functions. These costs also include our contributions to support industry and patient groups. Our professional fees consist primarily of accounting, information technology, legal and other consulting costs. We believe we have largely built out the structure to support a global multi-indication oncology company and will look to moderate general and administrative expense growth to achieve profitability.

In addition, we incur significant legal and accounting costs related to compliance with SEC rules and regulations, including the costs of achieving and maintaining compliance with Section 404 of the Sarbanes-Oxley Act of 2002 and compliance with rules of the NASDAQ Stock Market, as well as insurance, investor relations and other costs associated with being a public company.

50

Financial expenses, net

Financial expenses, net, primarily consists of bank fees, credit facility interest expense and related debt issuance costs, interest income from cash balances and short-term investments and gains (losses) from foreign currency transactions. Our reporting currency is the U.S. dollar. We have historically held substantially all of our cash balances in U.S. dollar denominated accounts to minimize the risk of translational currency exposure.

Critical accounting policies and estimates

In accordance with U.S. GAAP, in preparing our financial statements we must make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of net revenues and expenses during the reporting period. We develop and periodically change these estimates and assumptions based on historical experience and on various other factors that we believe are reasonable under the circumstances. Actual results may differ from these estimates.

The critical accounting policies requiring estimates, assumptions and judgments that we believe have the most significant impact on our consolidated financial statements are described below.

Revenue recognition

The amount of revenue recognized reflects the consideration to which we expect to be entitled to receive in exchange for our Products. For additional information, see Note 2(m) to the Consolidated Financial Statements.

We also receive revenues pursuant to the Zai Agreement. For additional information regarding the Zai Agreement, see Note 12 to the Consolidated Financial Statements.

Share-based compensation

Under the FASB's ASC 718, Compensation-Stock Compensation, we measure and recognize compensation expense for share options granted to our employees and directors and for our ESPP based on the fair value of the awards on the date of grant. The fair value of share options is estimated at the date of grant using the Black-Scholes option pricing model and for market condition awards we also use the Monte-Carlo simulation model. Both models requires management to apply judgment and make estimates, which include models of volatility, term, dividends and interest rates. The computation of expected volatility is based on the historical volatility of our shares. The expected term of options granted is calculated using our historical and future exercise behavior. Historically, we have not paid dividends and have no foreseeable plans to pay dividends. Therefore, we use an expected dividend yield of zero in the option pricing model. The risk-free interest rate is based on the yield of U.S. treasury bonds with equivalent terms.

For information about our ESPP, see Note 15 to the Consolidated Financial Statements.

We recognize share-based compensation costs only for those shares expected to vest over the requisite vesting period of the award, which is generally the option vesting term of four years, using the accelerated method.

We recognize compensation costs for the value of performance stock units ("PSU") over the performance period when the vesting conditions become probable in accordance with ASC 718.

The table below summarizes the assumptions that were used to estimate the fair value of the options granted to employees during the periods presented:

[[GREPCENT_TABLE]]
[["","","Year ended December 31,"],["","","2025","","2024","","2023"],["Expected term (years)","","5.50-5.79","","5.50-5.73","","5.50-6.00"],["Expected volatility","","75%-77%","","71%-73%","","63%-70%"],["Risk-free interest rate","","4.01%-4.02%","","3.88%-4.43%","","3.48%-4.79%"],["Dividend yield","","0.00","%","","0.00","%","","0.00","%"]]
[[/GREPCENT_TABLE]]

If any of the assumptions used in the Black-Scholes option pricing model change significantly, share-based compensation for future awards may differ materially from the awards granted previously.

So long as our ordinary shares are publicly traded in a liquid market, we will rely on the daily trading price of our ordinary shares when we estimate the fair value of options granted.

51

We incurred share-based compensation expense of $104.8 million, $160.0 million and $115.6 million during the years ended December 31, 2025, 2024 and 2023, respectively. As of December 31, 2025, we have unrecognized compensation expense of $73.8 million, which is expected to be recognized over a weighted average period of approximately 1.45 years years. We expect to continue to grant equity awards in the future, and to the extent that we do, our recognized share-based compensation expense will fluctuate as a significant portion of our awards are tied to our performance.

[Excerpt truncated for page length; the complete text is on the linked full-MD&A page.]

Read the full FY 2025 MD&A: /company/NVCR/mda/fy2025/
All MD&A years: /company/NVCR/mda/


## MD&A history

Prior-year 10-K MD&A spans are extracted from SEC filings with the same bounded parser used for the latest filing. Each year's full verbatim text is on its own sub-page.

- [FY 2024 MD&A](/company/NVCR/mda/fy2024/): filed 2025-02-27; accession 0001645113-25-000002 (https://www.sec.gov/Archives/edgar/data/1645113/000164511325000002/nvcr-20241231.htm)
- [FY 2023 MD&A](/company/NVCR/mda/fy2023/): filed 2024-02-22; accession 0001645113-24-000006 (https://www.sec.gov/Archives/edgar/data/1645113/000164511324000006/nvcr-20231231.htm)
- [FY 2022 MD&A](/company/NVCR/mda/fy2022/): filed 2023-02-23; accession 0001645113-23-000023 (https://www.sec.gov/Archives/edgar/data/1645113/000164511323000023/nvcr-20221231.htm)
- [FY 2021 MD&A](/company/NVCR/mda/fy2021/): filed 2022-02-24; accession 0001645113-22-000011 (https://www.sec.gov/Archives/edgar/data/1645113/000164511322000011/nvcr-20211231.htm)




## Macro cross-references

Indicators mapped to this company's SIC classification (industry 3841 Surgical & Medical Instruments & Apparatus) by grepcent's deterministic macro-sector crosswalk. A navigational mapping, not a statistical or causal claim.

- [INDPRO](/indicator/INDPRO/): Industrial Production: Total Index
- [TCU](/indicator/TCU/): Capacity Utilization: Total Index
- [PPIACO](/indicator/PPIACO/): Producer Price Index by Commodity: All Commodities
- [GDPC1](/indicator/GDPC1/): Real Gross Domestic Product
- [DGS10](/indicator/DGS10/): Market Yield on U.S. Treasury Securities at 10-Year Constant Maturity
- [FEDFUNDS](/indicator/FEDFUNDS/): Federal Funds Effective Rate
- [CES0500000003](/indicator/CES0500000003/): Average Hourly Earnings of All Employees, Total Private
- [PAYEMS](/indicator/PAYEMS/): All Employees, Total Nonfarm

Macro-to-micro threads including this sector: [Inflation (CPI / PCE / PPI)](/thread/inflation-cpi-pce-ppi/), [US labor market](/thread/us-labor-market/), [Growth & output](/thread/growth-output/), [Money & trade](/thread/money-trade/), [Government finances](/thread/government-finances/), [Sector employment](/thread/sector-employment/), [Industrial orders & inventories](/thread/industrial-orders/), [Trade & external](/thread/trade-external/).

All macro indicators: /indicators/


## For LLMs & downloads

Markdown twin: /company/NVCR.md · JSON record: /company/NVCR.json · verified financials: /company/NVCR/financials.json / /company/NVCR/financials.csv · machine TOC for the whole site: /llms.txt